XRTX - XORTX files application with FDA for trial of XRx-008 in kidney disease

XORTX Therapeutics (OTCQB:XRTXF) filed an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow a clinical study of XRx-008 to treat progressing kidney disease due to autosomal dominant polycystic kidney disease (ADPKD). The IND contains the protocol for the bridging pharmacokinetics study called XRX-OXY-101. "The Company looks forward to advancing this program through our planned clinical trials this year in patients with ADPKD," said XORTX CEO Allen Davidoff. The company said its XRx-008, for ADPKD, is a proprietary combination of uric acid lowering agents and other excipients.

For further details see:

XORTX files application with FDA for trial of XRx-008 in kidney disease